Myfembree denied due to quantity / dose limits by Cigna?

Cigna's specific coverage criteria for myfembree are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Limits Myfembree Quantities — and Why You Can Appeal

Myfembree (relugolix/estradiol/norethindrone acetate) is an oral once-daily combination hormone therapy approved for managing heavy menstrual bleeding due to uterine fibroids and the pain of endometriosis. Cigna, like most large commercial insurers, applies quantity-limit edits to this medication. These edits are triggered automatically at the pharmacy and are not a judgment that the drug is inappropriate for you — they reflect a formulary-management rule that limits the dispensed supply per fill or per plan year to a predetermined amount.

### Why This Denial Is Appealable

Quantity-limit denials are among the most routinely overturned on appeal. Federal law requires your plan to have a documented clinical basis for any coverage restriction. If your prescriber has determined that the prescribed quantity is medically necessary for your condition, the plan must evaluate that clinical judgment — not simply enforce an administrative counter. Both ACA Section 2719 (applicable to non-grandfathered commercial plans) and ERISA Section 503 (for employer-sponsored plans) guarantee you a full-and-fair internal review and, if that fails, an independent external review by a federally or state-certified organization that has no financial relationship with Cigna.

### Your Appeal Timeline

• Internal appeal: File within the timeframe printed on your denial letter (commonly 180 days). Cigna must decide within 30 days for a pre-service appeal or 60 days for a post-service appeal.
• External review: If the internal appeal is denied, you generally have four months from that denial to request external review. An independent reviewer's decision is binding on the plan.
• Expedited option: If your condition is urgent and a standard timeline would seriously jeopardize your health, request an expedited appeal — decisions are typically required within 72 hours.

### Documentation to Gather

1. Diagnosis confirmation — office notes, imaging, or pathology that establishes your diagnosis (uterine fibroids or endometriosis). 2. Clinical severity — chart documentation describing symptom burden (e.g., severity of bleeding, pain scores, impact on daily functioning) that justifies the prescribed supply. 3. Prior-treatment history — a dated list of other hormonal or non-hormonal therapies tried, with outcomes and reasons for discontinuation or inadequacy. 4. Prescriber medical-necessity letter — a signed letter from your provider explaining why the prescribed quantity is the minimum necessary to provide continuous, uninterrupted therapy and why a smaller fill would create a clinical gap or adherence risk.

### Criteria-Mapping Structure

Obtain two documents: (1) the FDA-approved prescribing information for Myfembree, which describes the approved indication and administration schedule, and (2) Cigna's published coverage policy or quantity-limit guideline for this drug (request it by name in your appeal). Create a table with one row per coverage requirement listed in those documents. In each row, record the requirement verbatim, then record the exact chart fact or clinical finding that satisfies it. Attach the supporting chart note or lab result as an exhibit. This side-by-side format directly addresses the reviewer's checklist and significantly strengthens your case.